Back to News
Oct 30, 2025 12:00 PM

Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges

Takeda Pharmaceutical Company Limited (NYSE:TAK) posted a second-quarter 2025 adjusted net profit of 201.6 billion Japanese yen (approximately $1.31 billion).

The company reported earnings per American Depositary Share (EPADS) of 43 cents, missing analyst expectations of 44 cents. However, in yen, earnings per share declined 4.5% to 128 yen.

Total sales for the quarter amounted to $7.52 billion (1.18 trillion yen), missing the consensus estimates of $8.08 billion.

Also Read: Takeda Taps Nabla Bio’s Generative AI Platform For Antibody Design In $1 Billion Pact

"Takeda's fiscal year 2025 first half results are consistent with our expectations for core business progress in this ...